CD8A and cancer: Monotherapy with NKTR-214 (an agonist targeting CD122) in cancer patients revealed increased expression of PD-1 and PD-L1 on the cell surface, along with a significant increase in NK cells and CD8+ T cells in patients, suggesting a potential synergistic mechanism of action of PD-1 inhibitors with NKTR-214 (184).